Session 321: Emerging Targets and Biomarkers Identification and Validation

Day 1: Afternoon, Thursday, July 25, 2019

Place: Room I, 2nd Floor

Chair: Dr. Nick Zhang, Chairman & CEO, MEDx (Suzhou) Translational Medicine Co., Ltd, China

Chair’s Introduction

Keynote Speech
Title: Overview of Biomarker Use in Disease Diagnosis and Management and Drug R&D
Dr. Laszlo Takacs, Professor, Department of Human Genetics, University of Debrecen, Hungary

Title: Artificial Neural Network Algorithms for Biomarker Discovery and Pathway Modelling
Dr. Graham Ball, Professor of Bioinformatics/CSO, Nottingham Trent University/CompanDX, UK

Title: Importance and Application of Biomarkers in Cancer Immunotherapy

Title: Exploratory Biomarker Testing: To Qualify or Validate the Assay? Overview of the Latest Scientific and Regulatory Considerations for Biomarker Validation

Dr. Afshin Safavi, Founder and Board Member, BioAgilytix Labs, USA

Title: Identification and Characterization of the Drug-target Interaction of a Novel Antibacterial Against Staphylococcus aureus YidC2, A Membrane Insertase

Dr. Hao-Chieh Chiu, Associate Professor, College of Medicine, National Taiwan University, Taiwan

Coffee Break

Session 322: Drug Design and Synthesis

Day 2: Morning, Friday, July 26, 2019

Place: Room I, 2nd Floor

Chair: Dr. Yinsheng Zhang, Senior R&D Director, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., China

Chair’s Introduction

Keynote Speech

Title: Design, Synthesis and Biological Evaluation of Carbohydrate-based Compounds as Potential Antitumor and Antiviral Agents

Dr. Yongmin Zhang, Research Director, CNRS-Sorbonne University, France

Title: Design and Synthesis of Deuterium-labeled Drugs as Internal Standards

Dr. Yinsheng Zhang, Senior R&D Director, Jiangsu Key Laboratory of Targeted Antiviral Research, Chia Tai Tianqing Pharmaceutical Group Co., China

Title: Structure-based Design and Synthesis of HPPK Inhibitors

Dr. Genbin Shi, Staff Scientist, Macromolecular Crystallography Laboratory, National Cancer Institute, USA

Title: Antimicrobial Activity of Novel Boron-based Inorganic-Organic Hybrid Compounds
Dr. Simon Duttwyler, Professor, Zhejiang University, China

Coffee Break

Title: Stereoselective Synthesis of Methylidenecoumarins and Methylideneuracils as Novel, Potent Anticancer Agents
Dr. Tomasz Janecki, Professor, Lodz University of Technology, Institute of Organic Chemistry, Poland

Title: Synthesis and Characterization of Chimeric Opioid Receptor Ligands in the Search for Analgesics with Limited Side Effects
Dr. Anna Janecka, Professor, Medical University of Lodz, Poland

Title: Spectrum of Biological Activities of Cinnamic acid Analogues
Dr. Josef Jampilek, Professor, Department of Analytical Chemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Slovakia; Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University Olomouc, Czech Republic

Title: Discovery of Low Molecular Weight Inhibitors of the Guanine Nucleotide Exchange Factor VAV1

Dr. Marc Gerspacher, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Switzerland

Session 323: Drug Design, Synthesis and Lead Compounds Discovery

Day 2: Afternoon, Friday, July 26, 2019

Place: Room G, 1st Floor

Chair: Dr. Ryszard Ostaszewski, Professor, Institute of Organic Chemistry PAS, Poland

Chair’s Introduction

Title: Fragment Hits and Leads: More Than Meets the Eye
Dr. Fabrizio Giordanetto, Head, Medicinal Chemistry, D. E. Shaw Research LLC, USA

Title: Synthesis of Novel, Peptidomimetic Kinase and Proteasome Inhibitors with Cytostatic/Cytotoxic Activity
Dr. Ryszard Ostaszewski, Professor, Institute of Organic Chemistry PAS, Poland

Title: Discovery and Characterization of Potent and Selective Cyclohexane-based CCR6 Inhibitors as Biological Probes

Mr. Taisuke Tawaraishi, Principal Scientist, Drug Discovery Chemistry Laboratories, Research, Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company, Japan

Title: Design of Novel Multivalent Ligands that Cross-link Opioid Receptors for the Treatment of Pain

Dr. Victor J. Hruby, Regents Professor, University of Arizona, USA

Title: Discovery of PC945, A Novel Anti-fungal Agent for Inhaled Administration

Dr. Stephen Young, VP, Business Development, Sygnature Discovery, UK

Coffee Break

Session 324: Novel Small Moleculer Drugs Discovery and Design

Day 3: Afternoon, Saturday, July 27, 2019

Place: Room G, 1st Floor

Chair: Dr. Richard C Bethell, Chief Scientific Officer, Medivir AB, Sweden

Chair’s Introduction

Title: Discovery of Mefunidone, A New Small Molecule Drug for Diabetic Nephropathy

Dr. Qianbin Li, Professor of Medicinal Chemistry, Central South University, China

Title: Long Residence Time Adenosine A1 Receptor Agonists Produce Sustained Wash-resistant Antilipolytic Effect in Rat Adipocytes

Dr. Dong Guo, Professor, Xuzhou Medical University, China

Title: Nucleotide Prodrugs for the Treatment of Cancer

Dr. Richard C Bethell, Chief Scientific Officer, Medivir AB, Sweden

Title: Boosting the Anti-cancer Potential of COOH-bearing PAK1-blockers (Ketorolac etc) by Increasing Their Cell-permeability via Click Chemistry

Dr. Hiroshi Maruta, Professor, PAK Research Center, Australia

Title: Structure-based Design of Novel Kinase Inhibitors

Dr. John Karanicolas, Associate Professor, Fox Chase Cancer Center, USA

Title: Zelnorm, An Agonist of 5-Hydroxytryptamine 4-Receptor, Acts as a Potential Antitumor Drug by Targeting JAK/STAT3 Signaling

Dr. Chenyang Zhao, Professor, Ocean University of China, China